Drug Profile
Semaglutide subcutaneous - Novo Nordisk
Alternative Names: 9931; NN-9535; NN-9536; NN-9931; NNC-0113-0217; Ozempic; WegovyLatest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Developer Gilead Sciences; Novo Nordisk
- Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Obesity; Type 2 diabetes mellitus
- Phase III Non-alcoholic steatohepatitis; Peripheral arterial disorders; Renal failure
- Phase II Liver cirrhosis
- Phase I Atherosclerosis
- No development reported Non-alcoholic fatty liver disease
Most Recent Events
- 11 Mar 2024 Interim efficacy and adverse events data from a phase III SELECT trial in obesity released by Novo Nordisk
- 08 Mar 2024 Launched for Obesity (In adolescents, In adults, In the elderly) in USA, Germany, Norway, United Arab Emirates, United Kingdom, Denmark (SC) prior to March 2024
- 08 Mar 2024 Launched for Obesity in Germany, Norway, Switzerland, Denmark, United Kingdom, United Arab Emirates (SC) prior to March 2024